WNCT

FDA Grants Priority Review for Addyi® (flibanserin) Paving the Way for Expanded Access to Treat Low Sexual Desire in Postmenopausal Women

Addyi is the first and only FDA-approved, hormone-free pill clinically proven to treat low sexual desire in women RALEIGH, N.C., July 24, 2025 /PRNewswire/ -- Sprout Pharmaceuticals today announced ...
KRQE Blogs

Unprecedented Abstract Highlights Addyi’s Remarkable Effects on Low Libido among Breast Cancer Patients

IRVINE, CA – July 5, 2023 – The Ad Firm is thrilled to announce the publication of an abstract by Sprout Pharmaceuticals, showcasing the remarkable effects of Addyi (flibanserin) on low libido among ...
AOL

FDA approves daily pill to treat low libido in women after menopause: What to know

On December 15, 2025, the U.S. FDA approved Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Addyi was previously approved ...
WMUR

FDA OKs libido-boosting pill for older women who have gone through menopause

U.S. health officials have expanded approval of a much-debated drug aimed at boosting female libido, saying the once-a-day pill can now be taken by postmenopausal women up to 65 years old.The ...
Yahoo

A Pill for Sexual Desire Reaches a New Group of Women

On Dec. 15, Sprout Pharmaceuticals received approval to use its pill, Addyi (flibanserin), to treat low sexual desire in women who are past menopause. Addyi works by addressing neurotransmitters like ...